Fundz

Celldex

Hampton, New Jersey, United States · Biotechnology, Health Care, Medical

Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders.

Key facts

Headquarters
Hampton, New Jersey, United States
Employees
190
Industries
Biotechnology, Health Care, Medical
Status
Public (CLDX)
Website
celldex.com
LinkedIn
Company page

Recent activity at Celldex

  • : SEC 8-K (8.01): On September 22, 2026, Celldex Therapeutics, Inc. issued a press release announcing the results from its two Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 clinical trials of Barzolvolimab, which targets chronic spontaneous urticaria (CSU). This announcement is significant as it communicates the outcomes of important clinical trials that may impact the company's future product offerings and market strategy. The results could influence investor sentiment and the stock performance of Celldex, as they pertain to the efficacy and potential approval of a new treatment. The press release is attached as Exhibit 99.1.
  • : SEC 8-K (5.02):
  • : SEC 8-K (5.02): On June 25, 2026, Celldex Therapeutics, Inc. conducted its 2026 Annual Meeting of Stockholders where significant corporate governance changes took place. Stockholders approved an amendment to the 2021 Omnibus Equity Incentive Plan, increasing the number of shares available for issuance under the plan by 3,400,000 shares, totaling 12,900,000. This amendment includes clarifications to tax withholding provisions on awards. Additionally, new directors were elected, with notable votes including Harry H. Penner, Jr. and Anthony S. Marucci, reflecting strong support with over 60 million votes for their re-election. The outcome of these proposals signifies strategic adjustments in the company's equity compensation approach and board composition, impacting future corporate governance and shareholder alignment.
  • : SEC 8-K (1.01): On April 1, 2026, Celldex Therapeutics, Inc. entered into a significant Underwriting Agreement with Leerink Partners LLC and TD Securities (USA) LLC for the public offering of 10,345,000 shares of its common stock at $29.00 per share. The total expected net proceeds from this Offering are approximately $282 million, after deductions for underwriting discounts, commissions, and other expenses. The Offering is anticipated to close around April 6, 2026, pending customary closing conditions, and includes a 30-day option for the Underwriters to acquire an additional 1,551,750 shares. This strategic move enhances the company's financial resources, positioning it for future growth and operational developments.
  • : SEC 8-K (1.01): On April 1, 2026, Celldex Therapeutics, Inc. entered into an underwriting agreement with Leerink Partners LLC and TD Securities (USA) LLC for the offering of 10,345,000 shares of its common stock at a public price of $29.00 per share. The anticipated net proceeds from this offering are approximately $282 million after deducting underwriting discounts and expenses. The offering is projected to close around April 6, 2026, contingent on customary closing conditions. This agreement indicates a significant capital raise for the company, which may impact its strategic operations and funding for future initiatives.
  • : Celldex Therapeutics Appoints Teri Lawver as Chief Commercial Officer
  • : Celldex Therapeutics, Inc.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Celldex funding history

DateRoundAmount
Nov 2016Venture$62.5M

Leadership

  • Chandler Ruehrwein, Senior Director Human Resources
  • Bradley Bloom, Vice President Clinical Development
  • Neil Wishart, VP of Clinical Strategy
  • Vernika Dahiya, Talent Sourcing Recruiter
  • Teri Lawver, Chief Commercial Officer

Verified email and direct lines for Celldex’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Celldex in the news

Companies similar to Celldex

About Celldex: questions and answers

What does Celldex do?

Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders.

Where is Celldex headquartered?

Celldex is headquartered in Hampton, New Jersey, United States.

How many employees does Celldex have?

Celldex has about 190 employees.

Has Celldex raised funding?

Yes. Fundz has recorded 1 funding event for Celldex. The most recent, $62.5M, was in Nov 2016.

Who leads Celldex?

Bradley Bloom is a Vice President Clinical Development at Celldex.

What is the latest news on Celldex?

On Apr 1, 2026, SEC 8-K (8.01): On September 22, 2026, Celldex Therapeutics, Inc. issued a press release announcing the results from its two Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 clinical trials of Barzolvolimab, which targets chronic spontaneous urticaria (CSU). This announcement is significant as it communicates th

Is Celldex a public company?

Yes. Celldex is publicly traded under the ticker CLDX.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Celldex across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.